Molecular Imaging Market Future Growth By Leading Key Players: Carestream Health, Fujifilm Holdings Corporation, GE Healthcare, Hitachi Ltd, Hologic, Inc., Siemens AG

Defining disease processes based on their molecular and cellular changes and advances in genomics offer promise for earlier disease detection and molecular prevention in some cases. The field of molecular imaging is adopting these advances and is using various technologies to study disease states and physiology. For instance, optical methods, such as variations of fluorescence imaging, can resolve tissue microstructures or target specific cells using molecular probes. Mass spectrometry offers a new modality for molecular imaging in image-guided surgery by providing detailed information of the chemical makeup of surgical tissue without the need for molecular probes.

Request Sample Report@ https://www.coherentmarketinsights.com/insight/request-sample/2191

Molecular imaging is generally used to improve the diagnosis and treatment of lung cancer. In breast cancer, molecular imaging is used to minimize the removal of axillary lymph nodes by determining which nodes are most likely to contain cancer cells. For many gastrointestinal cancers, PET-CT, a molecular imaging technology, is able to identify cancer invasion in the body and assess patient response to chemotherapy. It is also useful in colorectal cancer diagnosis and treatment by providing useful information that directly affects treatment options.

Manufacturers are focused on research and development to integrate advanced medical technologies for in vitro diagnosis. For instance, in 2014, Philips Healthcare received the U.S. FDA approval for spectral imaging system (IQon Spectral CT). The IQon Spectral CT is a leading, new, high standard for medical imaging. As per the study conducted by Radiological Society of North America, in 2013, Philips IQon Spectral CT system exhibited enhanced diagnosis in up to 70% cases as compared to conventional imaging methods.

With rapid technological advancements, targeted therapy, presymptomatic detection, and personalized medicine are possible in future with the use multimodal molecular imaging. Moreover, researchers are using molecular imaging to identify the strategies for developing new drugs and to design clinical trials to test their effectiveness. Information provided by molecular imaging technologies has the potential to accelerate the drug development and approval process by making it less expensive and more effective.

Increasing prevalence of various chronic diseases such as cancer and other genetic disorders are propelling demand for early disease diagnosis eventually driving the medical imaging market growth. According to the Centers for Disease Control and Prevention (CDC), February 2018 data, in the U.S., around 22,000 men and 9,000 women suffer from liver cancer, and around 16,000 men and 8,000 women die from liver cancer annually. Molecular imaging has become part of standard care for many types of cancer. The use of imaging techniques in early cancer detection, treatment response, and new therapy development is steadily growing and has already significantly impacted on clinical management of cancer.

Request Customization Report@ https://www.coherentmarketinsights.com/insight/request-customization/2191

Moreover, rising cases of neurological disorders such as Alzheimer’s, which can be easily detected with PET-CT scanner is also contributing to the medical imaging market growth. For instance, according to the Alzheimer’s Association, in 2017, over 5 million people were estimated to be suffering from Alzheimer’s disease, which was also reported to be the sixth-leading cause of death in the U.S. However, some limitations associated with molecular modalities including side effects of radiation and lack of penetration depth, which is expected to confine the molecular imaging market growth to some extent.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.